

Maria Lia Scribano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8062043/publications.pdf>

Version: 2024-02-01

48
papers

3,527
citations

346980

22
h-index

252626

46
g-index

49
all docs

49
docs citations

49
times ranked

4411
citing authors

#	ARTICLE	IF	CITATIONS
1	Female reproductive health and inflammatory bowel disease: A practice-based review. <i>Digestive and Liver Disease</i> , 2022, 54, 19-29.	0.4	16
2	Incident Colorectal Cancer in Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 721.	1.7	5
3	Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110724.	1.4	14
4	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
5	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
6	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 507-516.	1.6	11
7	Vitamin D Signaling in Gastro-Rheumatology: From Immuno-Modulation to Potential Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2456.	1.8	4
8	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, . .	0.4	2
9	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1432-1441.	1.9	11
10	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102457.	2.5	18
11	Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2855-2864.	1.1	9
12	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	1.4	11
13	Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. <i>Digestive and Liver Disease</i> , 2019, 51, 346-351.	0.4	5
14	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	0.9	33
15	Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. <i>Lancet</i> , The, 2019, 393, 1699-1707.	6.3	155
16	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
17	Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , 2019, 10, 47.	1.6	14
18	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2019, 51, 640-647.	0.4	14

#	ARTICLE	IF	CITATIONS
19	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.4	22
20	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. <i>World Journal of Gastroenterology</i> , 2018, 24, 2457-2467.	1.4	61
21	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	7
22	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
23	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 913-924.	0.6	30
24	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
25	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016, 65, 82-90.	6.1	91
26	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1104-1113.	13.9	366
27	Role of Rifaximin in Inflammatory Bowel Disease Treatment. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 16, 225-229.	1.1	3
28	Budesonide multi-matrix system formulation for treating ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 741-743.	0.9	6
29	Mucosal Healing With Thalidomide in Refractory Crohn's Disease Patients Intolerant of Anti-TNF- α Drugs. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 530-533.	1.1	15
30	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	0.6	53
31	Antibiotics and Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2013, 31, 379-384.	0.8	24
32	Use of antibiotics in the treatment of Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 648.	1.4	28
33	Rifaximin and Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 7487.	1.4	0
34	Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2012, 142, 473-481.e4.	0.6	165
35	Randomized Controlled Trials in Steroid Dependent and in Severe Colitis. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 314-320.	0.4	0
36	Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 329-333.	1.0	42

#	ARTICLE	IF	CITATIONS
37	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1168-1170.	0.9	21
38	Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1117-1125.	1.9	189
39	Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with <i>Lactobacillus GG</i> . <i>Gut</i> , 2002, 51, 405-409.	6.1	492
40	Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission. <i>American Journal of Gastroenterology</i> , 2000, 95, 1213-1220.	0.2	363
41	Treatment of Esophageal Crohn's Disease by Enteral Feeding via Percutaneous Endoscopic Gastrostomy. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 176-179.	1.3	12
42	Antibiotic Use in Crohn's Disease. <i>BioDrugs</i> , 1997, 8, 293-306.	2.2	14
43	Mortality among patients with ulcerative colitis: Rome 1970-1989. <i>European Journal of Epidemiology</i> , 1997, 13, 189-194.	2.5	23
44	Long-term symptom patterns in duodenal ulcer: Psychosocial factors. <i>Journal of Psychosomatic Research</i> , 1996, 41, 465-472.	1.2	23
45	Psychologic Predictors of Duodenal Ulcer Healing. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 84-89.	1.1	30
46	Patterns of Biologic and Psychologic Risk Factors in Duodenal Ulcer Patients. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 110-117.	1.1	36
47	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. <i>Gastroenterology</i> , 1995, 108, 345-349.	0.6	197
48	Development of the perceived stress questionnaire: A new tool for psychosomatic research. <i>Journal of Psychosomatic Research</i> , 1993, 37, 19-32.	1.2	731